9.74
price up icon3.51%   0.33
after-market Handel nachbörslich: 9.76 0.02 +0.21%
loading
Schlusskurs vom Vortag:
$9.41
Offen:
$9.41
24-Stunden-Volumen:
1.18M
Relative Volume:
2.18
Marktkapitalisierung:
$507.43M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-7.5504
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
+4.96%
1M Leistung:
+9.81%
6M Leistung:
+13.39%
1J Leistung:
+126.25%
1-Tages-Spanne:
Value
$9.29
$10.03
1-Wochen-Bereich:
Value
$8.58
$10.03
52-Wochen-Spanne:
Value
$4.20
$10.03

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name
Firmenname
Zevra Therapeutics Inc
Name
Telefon
(321) 939-3416
Name
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-11
Name
Neueste SEC-Einreichungen
Name
ZVRA's Discussions on Twitter

Vergleichen Sie ZVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZVRA
Zevra Therapeutics Inc
9.74 507.43M 27.46M -46.05M -33.83M -1.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-08 Fortgesetzt Cantor Fitzgerald Overweight
2024-10-07 Eingeleitet Guggenheim Buy
2024-09-24 Eingeleitet JMP Securities Mkt Outperform
2024-09-24 Bestätigt Maxim Group Buy
2024-04-02 Bestätigt Maxim Group Buy
2024-03-12 Eingeleitet William Blair Outperform
2023-03-17 Eingeleitet Maxim Group Buy
Alle ansehen

Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten

pulisher
Jun 14, 2025

Zevra Therapeutics’ SWOT analysis: strong MIPLYFFA launch boosts stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Squarepoint Ops LLC Purchases 4,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Trend Tracker for (ZVRA) - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 09, 2025

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 09, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ZVRAForm DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material - mx.advfn.com

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Buys New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 6,877 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Deutsche Bank AG - Defense World

May 31, 2025
pulisher
May 30, 2025

Zevra Therapeutics confirms board members through stockholder vote By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders - The Manila Times

May 30, 2025
pulisher
May 29, 2025

Zevra Announces Final Results of 2025 Annual Meeting of Stockhol - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Zevra Therapeutics Elects New Directors at Annual Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Zevra Therapeutics confirms board members through stockholder vote - Investing.com

May 29, 2025
pulisher
May 29, 2025

Zevra Stockholders Overwhelmingly Reject Opposition, Back Current Board with 74% Support - Stock Titan

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Purchases Shares of 25,075 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

May 29, 2025
pulisher
May 28, 2025

Trading (ZVRA) With Integrated Risk Controls - news.stocktradersdaily.com

May 28, 2025
pulisher
May 27, 2025

Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com Nigeria

May 27, 2025
pulisher
May 27, 2025

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - Insider Monkey

May 27, 2025
pulisher
May 26, 2025

Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential - Investing.com

May 26, 2025
pulisher
May 26, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Analysts - Defense World

May 26, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Buy” - Defense World

May 24, 2025
pulisher
May 23, 2025

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

May 23, 2025
pulisher
May 22, 2025

Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News

May 22, 2025
pulisher
May 22, 2025

Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26% - simplywall.st

May 22, 2025
pulisher
May 22, 2025

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

ZVRA Receives Proxy Advisory Firms' Recommendations for Annual Meeting | ZVRA Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

All Three Leading Proxy Advisory FirmsISS, Glass Lewis, and Egan-JonesRecommend Zevra Stockholders Vote FOR the Company's Director Nominees - The Manila Times

May 21, 2025
pulisher
May 19, 2025

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst - Defense World

May 19, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

May 18, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Brokers Boost Earnings Estimates for ZVRA - Defense World

May 18, 2025
pulisher
May 18, 2025

What is William Blair’s Estimate for ZVRA Q1 Earnings? - Defense World

May 18, 2025
pulisher
May 17, 2025

Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reach - MSN

May 17, 2025
pulisher
May 17, 2025

Q2 EPS Forecast for Zevra Therapeutics Lifted by Analyst - Defense World

May 17, 2025
pulisher
May 16, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA) - Defense World

May 16, 2025
pulisher
May 15, 2025

Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success - TipRanks

May 15, 2025
pulisher
May 15, 2025

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail

May 15, 2025
pulisher
May 15, 2025

Zevra Therapeutics (ZVRA) Reports Strong Q1 Performance, Bolstered by Capital Infusion - GuruFocus

May 15, 2025
pulisher
May 14, 2025

ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Ratin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views - Benzinga

May 14, 2025
pulisher
May 14, 2025

ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Rating | ZVRA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? - Benzinga

May 14, 2025
pulisher
May 14, 2025

Zevra Therapeutics (ZVRA) Target Price Increased by Analyst | ZV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance - TipRanks

May 14, 2025
pulisher
May 14, 2025

Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP - TipRanks

May 14, 2025

Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):